Association Between Circulating BDNF Levels and Cardioembolic Strokes in Patients Treated for Isc… (NCT07624396) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Association Between Circulating BDNF Levels and Cardioembolic Strokes in Patients Treated for Ischemic Stroke
France150 participantsStarted 2026-06
Plain-language summary
Atrial fibrillation (AF) is associated with serious complications, including embolic strokes, heart failure, and mortality. Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, increases the risk of thrombus formation. Once dislodged from the atrial cavity and traveling to the cerebral arteries, these thrombi can cause a cardioembolic stroke. The main risk factors for atrial cardiomyopathy (ACM) and AF are metabolic syndrome and aging.
ACM is a condition that is difficult to diagnose because it is not clearly defined, except through histological analysis. Guided by the results of our experimental approaches, the investigators aim to address this challenge by examining ACM through the lens of one of its complications: cardioembolic stroke. BDNF (Brain-Derived Neurotrophic Factor) is a neurotrophic factor involved in inflammatory and metabolic processes that may play a key role in the development of these complications.
This study explores the association between circulating levels of BDNF and the morphological and metabolic characteristics of ACM, as assessed by cardiac and brain imaging studies
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Individuals who provided informed consent
* Diagnosis of acute ischemic stroke confirmed by brain imaging (CT or MRI)
* Patient admitted to the USINV of the Department of General, Vascular, and Degenerative Neurology at the Dijon Bourgogne University Hospital during the inclusion period
* Underwent a combined cardiac and brain CT scan within 24 hours of admission for stroke
Exclusion Criteria:
* A person subject to a legal protective measure (guardianship, conservatorship)
* A person subject to a judicial safeguard measure
* A pregnant woman, a woman who has recently given birth, or a breastfeeding woman
* An adult who is legally incapacitated or unable to give consent,
* A minor
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Diagnosis of cardioembolic stroke according to the TOAST classification, adjudicated with a blinded review of biomarker data by the treating of a neurologist upon the patient' s hospital discharge.
Timeframe: At hospital discharge (approximately 5 to 10 day after admission)